top of page

Free Biopharma Daily Stock Updates - 01/28/22

$XBI $88.58 | +3.59%

 

Covid Updates

$SRNE +2.8% Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron. source


$NVAX +13.7% Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine. source



Pipeline Updates

$INCY +3.7% Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis. source


$BPMC +2.2% Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis. source


$CALT +5.4% Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™. source


$ALXO +5.9% ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer. source


$HUMA -7.6% Humacyte Announces Preclinical Results of Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting. source



Business Updates

$CPRX +4.3% Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst. source


$IMAB +6.8% I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs. source


$AMTI +9.5% Entered into stock purchase agreement with SVB Leerink and JMP Securities. source



 

Posted by DV/FS

0 comments

Comments


bottom of page